Neurogene (NGNE) Competitors

Neurogene (NASDAQ:NGNE) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.

Is NGNE or AVDL more profitable?

Neurogene has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Neurogene's return on equity of -32.81% beat Avadel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-32.81%	-27.96%
Avadel Pharmaceuticals	-52.53%	-93.34%	-44.77%

Does the media favor NGNE or AVDL?

In the previous week, Avadel Pharmaceuticals had 2 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Avadel Pharmaceuticals and 3 mentions for Neurogene. Avadel Pharmaceuticals' average media sentiment score of 1.36 beat Neurogene's score of 0.91 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avadel Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in NGNE or AVDL?

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 9.9% of Neurogene shares are owned by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer NGNE or AVDL?

Neurogene currently has a consensus target price of $47.20, suggesting a potential upside of 193.99%. Avadel Pharmaceuticals has a consensus target price of $19.88, suggesting a potential upside of 127.59%. Given Neurogene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurogene is more favorable than Avadel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Avadel Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer NGNE or AVDL?

Avadel Pharmaceuticals received 321 more outperform votes than Neurogene when rated by MarketBeat users. However, 96.67% of users gave Neurogene an outperform vote while only 66.54% of users gave Avadel Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Neurogene	Outperform Votes 29 96.67%	Underperform Votes 1 3.33%
Avadel Pharmaceuticals	Outperform Votes 350 66.54%	Underperform Votes 176 33.46%

Which has more risk & volatility, NGNE or AVDL?

Neurogene has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Which has better earnings and valuation, NGNE or AVDL?

Neurogene has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$925K	247.54	-$36.32M	-$4.27	-3.76
Avadel Pharmaceuticals	$169.12M	4.99	-$160.28M	-$0.52	-16.79

Summary

Neurogene beats Avadel Pharmaceuticals on 11 of the 19 factors compared between the two stocks.